Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli

Vaccine

Volumn 25, Issue 51, 2007, Pages 8574-8584

  Roland, Kenneth L ^a   Cloninger, Cheryl ^a   Kochi, Sims K ^a   Thomas, Lawrence J ^a   Tinge, Steven A ^a   Rouskey, Craig ^a,b   Killeen, Kevin P ^a  

^a AVANT Immunotherapeutics Inc   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

ETEC; Oral bivalent vaccine; Vibrio cholerae

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; CHOLERAGARDE; IMMUNOGLOBULIN G; PERU 15 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY TITER; ARTICLE; CHOLERA; CONSERVATIONAL SEED BANK; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG MANUFACTURE; DRUG TOLERABILITY; ENTEROTOXIGENIC ESCHERICHIA COLI; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SINGLE DRUG DOSE; TRANSCRIPTION REGULATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CHOLERA TOXIN; CHOLERA VACCINES; CULTURE MEDIA; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENTEROTOXIGENIC ESCHERICHIA COLI; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI INFECTIONS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PLASMIDS; RABBITS; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 36549072010     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.074     Document Type: Article

References (49)

1. Black R.E. Epidemiology of travelers' diarrhea and relative importance of various pathogens. Rev Infect Dis 12 Suppl 1 (1990) S73-S79
2. Gaastra W., and Svennerholm A.M. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 4 11 (1996) 444-452
3. Adachi J.A., Ericsson C.D., Jiang Z.D., DuPont M.W., Pallegar S.R., and DuPont H.L. Natural history of enteroaggregative and enterotoxigenic Escherichia coli infection among US travelers to Guadalajara, Mexico. J Infect Dis 185 11 (2002) 1681-1683
4. Bouckenooghe A.R., Jiang Z.D., De La Cabada F.J., Ericsson C.D., and DuPont H.L. Enterotoxigenic Escherichia coli as cause of diarrhea among Mexican adults and US travelers in Mexico. J Travel Med 9 3 (2002) 137-140
5. Jiang Z.D., Lowe B., Verenkar M.P., Ashley D., Steffen R., Tornieporth N., et al. Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis 185 4 (2002) 497-502
6. Wolf M.K., Taylor D.N., Boedeker E.C., Hyams K.C., Maneval D.R., Levine M.M., et al. Characterization of enterotoxigenic Escherichia coli isolated from US troops deployed to the Middle East. J Clin Microbiol 31 4 (1993) 851-856
7. Qadri F., Das S.K., Faruque A.S., Fuchs G.J., Albert M.J., Sack R.B., et al. Prevalence of toxin types and colonization factors in enterotoxigenic Escherichia coli isolated during a 2-year period from diarrheal patients in Bangladesh. J Clin Microbiol 38 1 (2000) 27-31
8. Oyofo B.A., Subekti D.S., Svennerholm A.M., Machpud N.N., Tjaniadi P., Komalarini T.S., et al. Toxins and colonization factor antigens of enterotoxigenic Escherichia coli among residents of Jakarta Indonesia. Am J Trop Med Hyg 65 2 (2001) 120-124
9. Al-Abri S.S., Beeching N.J., and Nye F.J. Traveller's diarrhoea. Lancet Infect Dis 5 6 (2005) 349-360
10. Serichantalergs O., Nirdnoy W., Cravioto A., LeBron C., Wolf M., Svennerholm A.M., et al. Coli surface antigens associated with enterotoxigenic Escherichia coli strains isolated from persons with traveler's diarrhea in Asia. J Clin Microbiol 35 6 (1997) 1639-1641
11. Steffen R. Epidemiology of traveler's diarrhea. Clin Infect Dis 41 Suppl 8 (2005) S536-S540
12. Hirst T.R. Cholera toxin and Escherichia coli heat-labile enterotoxin. In: Alouf J.E., and Freer J.H. (Eds). The Comprehensive Sourcebook of Bacterial Protein Toxins (1999), Academic Press, San Diego 104-129
13. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158 2 (1988) 372-377
14. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila L., Oksanen P., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338 8778 (1991) 1285-1289
15. Wolf M.K. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin Microbiol Rev 10 4 (1997) 569-584
16. Steinsland H., Valentiner-Branth P., Gjessing H.K., Aaby P., Molbak K., and Sommerfelt H. Protection from natural infections with enterotoxigenic Escherichia coli: longitudinal study. Lancet 362 9380 (2003) 286-291
17. Qadri F., Svennerholm A.M., Faruque A.S., and Sack R.B. Enterotoxigenic Escherichia coli in developing countries: epidemiology, microbiology, clinical features, treatment, and prevention. Clin Microbiol Rev 18 3 (2005) 465-483
18. Ahren C.M., and Svennerholm A.M. Experimental enterotoxin-induced Escherichia coli diarrhea and protection induced by previous infection with bacteria of the same adhesin or enterotoxin type. Infect Immunol 50 1 (1985) 255-261
19. Estrada-Garcia M.T., Jiang Z.D., Adachi J., Mathewson J.J., and DuPont H.L. Intestinal immunoglobulin a response to naturally acquired enterotoxigenic Escherichia coli in US travelers to an endemic area of Mexico. J Travel Med 9 5 (2002) 247-250
20. Jiang Z.D. Relationship between Enterotoxigenic Escherichia coli and Travelers' Diarrhea in Mexico, from 1992 to 1997 (1998), University of Texas, Houston, TX
21. Rockabrand D.M., Shaheen H.I., Khalil S.B., Peruski Jr. L.F., Rozmajzl P.J., Savarino S.J., et al. Enterotoxigenic Escherichia coli colonization factor types collected from 1997 to 2001 in US military personnel during operation Bright Star in northern Egypt. Diagn Microbiol Infect Dis 55 1 (2006) 9-12
22. Steffen R., Castelli F., Dieter Nothdurft H., Rombo L., and Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. J Travel Med 12 2 (2005) 102-107
23. Sack D.A., Sack R.B., Shimko J., Gomes G., O'Sullivan D., Metcalfe K., et al. Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers. J Infect Dis 176 1 (1997) 201-205
24. Scerpella E.G., Sanchez J.L., Mathewson I.J., Torres-Cordero J.V., Sadoff J.C., Svennerholm A.M., et al. Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea. J Travel Med 2 1 (1995) 22-27
25. Leyten E.M., Soonawala D., Schultsz C., Herzog C., Ligthelm R.J., Wijnands S., et al. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study. Vaccine 23 43 (2005) 5120-5126
26. Cryz Jr. S.J., Levine M.M., Kaper J.B., Furer E., and Althaus B. Randomized double-blind placebo controlled trial to evaluate the safety and immunogenicity of the live oral cholera vaccine strain CVD 103-HgR in Swiss adults. Vaccine 8 6 (1990) 577-580
27. Hirst T.R., Sanchez J., Kaper J.B., Hardy S.J., and Holmgren J. Mechanism of toxin secretion by Vibrio cholerae investigated in strains harboring plasmids that encode heat-labile enterotoxins of Escherichia coli. Proc Natl Acad Sci USA 81 24 (1984) 7752-7756
28. Ryan E.T., Crean T.I., Kochi S.K., John M., Luciano A.A., Killeen K.P., et al. Development of a Delta glnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cholerae. Infect Immunol 68 1 (2000) 221-226
29. Klose K.E., and Mekalanos J.J. Distinct roles of an alternative sigma factor during both free-swimming and colonizing phases of the Vibrio cholerae pathogenic cycle. Mol Microbiol 28 3 (1998) 501-520
30. Kenner J.R., Coster T.S., Taylor D.N., Trofa A.F., Barrera-Oro M., Hyman T., et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 172 4 (1995) 1126-1129
31. Yanisch-Perron C., Vieira J., and Messing J. Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. Gene 33 1 (1985) 103-119
32. Ryan E.T., Butterton J.R., Zhang T., Baker M.A., Stanley Jr. S.L., and Calderwood S.B. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody responses in mice. Infect Immunol 65 8 (1997) 3118-3125
33. Tauschek M., Gorrell R., Strugnell R., and Robins-Browne R. Identification of a protein secretory pathway for the secretion of heat-labile enterotoxin by an enterotoxigenic strain of Escherichia coli. Proc Natl Acad Sci USA 99 10 (2002) 7066-7071
34. Linnetz E.G., Borrelli K.M., Mazzola A.M., Ryan G.S., Sikes K.B., Kearney M.A., et al. Optimization of a rabbit model of attenuated Vibrio cholerae immunogenicity. Contemp. Topics 43 4 (2004) 58
35. Glenn G.M., Villar C.P., Flyer D.C., Bourgeois A.L., McKenzie R., Lavker R.M., et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect Immunol 75 5 (2007) 2163-2170
36. Isaka M., Komiya T., Takahashi M., Yasuda Y., Taniguchi T., Zhao Y., et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22 23-24 (2004) 3061-3068
37. Matousek M.P., Nedrud J.G., and Harding C.V. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages. J Immunol 156 11 (1996) 4137-4145
38. Boutonnier A., Villeneuve S., Nato F., Dassy B., and Fournier J.M. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid. Infect Immunol 69 5 (2001) 3488-3493
39. Cabrera O., Martinez M.E., Cuello M., Soto C.R., Valmaseda T., Cedre B., et al. Preparation and evaluation of Vibrio cholerae O1 EL Tor Ogawa lipopolysaccharide-tetanus toxoid conjugates. Vaccine 24 Suppl 2 (2006) S2-74-5
40. Bergquist C., Lagergard T., Lindblad M., and Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immunol 63 5 (1995) 2021-2025
41. Sverremark E., and Fernandez C. Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512. Immunology 92 1 (1997) 153-159
42. Galen J.E., and Levine M.M. Can a 'flawless' live vector vaccine strain be engineered?. Trends Microbiol 9 8 (2001) 372-376
43. Gentschev I., Dietrich G., Spreng S., Neuhaus B., Maier E., Benz R., et al. Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain. Int J Med Microbiol 294 6 (2004) 363-371
44. Stratford R., McKelvie N.D., Hughes N.J., Aldred E., Wiseman C., Curtis J., et al. Optimization of Salmonella enterica serovar Typhi Delta aroC Delta ssaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters. Infect Immunol 73 1 (2005) 362-368
45. Khan S., Chatfield S., Stratford R., Bedwell J., Bentley M., Sulsh S., et al. Ability of SPI2 mutant of S. typhi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 25 21 (2007) 4175-4182
46. Clements J.D., and El-Morshidy S. Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas. Infect Immunol 46 2 (1984) 564-569
47. Nashar T.O., Webb H.M., Eaglestone S., Williams N.A., and Hirst T.R. Potent immunogenicity of the B subunits of Escherichia coli heat-labile enterotoxin: receptor binding is essential and induces differential modulation of lymphocyte subsets. Proc Natl Acad Sci USA 93 1 (1996) 226-230
48. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 25 18 (2007) 3684-3691
49. Sack D.A., Shimko J., Torres O., Bourgeois A.L., Francia D.S., Gustafsson B., et al. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 25 22 (2007) 4392-4400